Kyverna Therapeutics (NASDAQ:KYTX) Posts Earnings Results, Beats Expectations By $0.05 EPS

Kyverna Therapeutics (NASDAQ:KYTX) issued its quarterly earnings data on Wednesday. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.05, FiscalAI reports.

Kyverna Therapeutics Stock Performance

Shares of KYTX opened at $8.08 on Friday. The company has a current ratio of 8.15, a quick ratio of 8.15 and a debt-to-equity ratio of 0.13. The stock has a market cap of $499.67 million, a P/E ratio of -2.75 and a beta of 1.93. The company has a 50-day moving average of $8.06 and a two-hundred day moving average of $8.44. Kyverna Therapeutics has a 12-month low of $3.27 and a 12-month high of $13.67.

Key Headlines Impacting Kyverna Therapeutics

Here are the key news stories impacting Kyverna Therapeutics this week:

• Positive Sentiment: HC Wainwright improved its estimates for Q3 2026 EPS to $(0.66) from $(0.78), FY2026 EPS to $(2.70) from $(2.98), and FY2027 EPS to $(2.79) from $(3.01). Estimates for Q4 2026, Q1 2027, Q2 2027, Q3 2027 and Q4 2027 were also raised, indicating expectations for better-than-previously-anticipated cost control or operating progress. The $25 target implies substantial upside from the stock’s recent level near $8. MarketBeat Kyverna Therapeutics analyst information
• Positive Sentiment: Kyverna’s second-quarter 2026 results reportedly included pipeline progress, and the company’s quarterly loss of $(0.63) per share was better than the $(0.68) analyst consensus. The earnings beat provides additional support for the improved forecasts. Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
• Neutral Sentiment: Despite the estimate increases, HC Wainwright still projects losses in every listed period, including $(2.70) per share for FY2026 and $(2.79) for FY2027. Investors will likely continue to focus on clinical milestones, cash resources and the company’s ability to advance its cell-therapy pipeline.

Institutional Trading of Kyverna Therapeutics

Hedge funds have recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its holdings in shares of Kyverna Therapeutics by 16.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,762,617 shares of the company’s stock valued at $16,569,000 after purchasing an additional 250,418 shares during the period. Adage Capital Partners GP L.L.C. bought a new position in shares of Kyverna Therapeutics in the 4th quarter worth approximately $15,667,000. Vanguard Group Inc. lifted its stake in shares of Kyverna Therapeutics by 0.8% in the third quarter. Vanguard Group Inc. now owns 1,322,625 shares of the company’s stock worth $7,936,000 after buying an additional 9,858 shares in the last quarter. Balyasny Asset Management L.P. bought a new stake in Kyverna Therapeutics during the fourth quarter valued at approximately $9,220,000. Finally, Alyeska Investment Group L.P. purchased a new position in Kyverna Therapeutics in the 4th quarter worth approximately $5,640,000. Institutional investors and hedge funds own 18.08% of the company’s stock.

Analysts Set New Price Targets

KYTX has been the topic of several analyst reports. Wall Street Zen downgraded Kyverna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of Kyverna Therapeutics in a research note on Wednesday, June 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Wednesday, June 24th. Finally, JPMorgan Chase & Co. reduced their price target on Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 13th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Kyverna Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $30.00.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical?stage biotechnology company dedicated to developing engineered regulatory T?cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen?specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.